Research and Practice in Thrombosis and Haemostasis

Title Publication Date Language Citations
HTRS2023.P2.10 Structured assessments and clinical phenotypes in bleeding of unknown cause2023/08/01English
HTRS2023.O8A.2 Exercise capacity is reduced in children and adolescents following pulmonary embolism2023/08/01English
HTRS2023.O6B.1 Interaction of antithrombin with vascular GAGs is required for its anti-inflammatory signaling but not anticoagulant protease-inhibitory function2023/08/01English
HTRS2023.P3.4 EAGeR (Empower Adolescent Girls): a multidisciplinary approach to iron deficiency anemia related to heavy menstrual bleeding2023/08/01English
HTRS2023.P4.18 Improving anticoagulation care for pediatric oncology patients2023/08/01English
HTRS2023.P2.15 Treatment burden, patient preference, and health-related quality of life in patients with hemophilia A or B with inhibitors on concizumab prophylaxis: results from the phase 3 explorer7 study2023/08/01English
HTRS2023.P4.4 DOAC compared with warfarin for VTE in underweight patients: a retrospective cohort study conducted through the VENUS Network2023/08/01English
HTRS2023.P4.7 Outcomes of pulmonary embolism in patients with autoimmune hemolytic anemia: a National Inpatient Sample (NIS) study2023/08/01English
HTRS2023.O8C.4 Subject with infertility due to congenital plasminogen deficiency type 1: results of plasminogen replacement therapy and impact of varying dosage regimen during treatment and maintenance phases2023/08/01English
HTRS2023.P1.4 Characterization of the binding interaction between factor XII and integrin αIIbβ32023/08/01English
HTRS2023.O8B.3 Elucidating the molecular mechanism of excessive phosphatidylserine exposure in sickle red cells2023/08/01English
HTRS2023.P3.2 Clinical outcomes in patients with acute hepatic porphyria treated with givosiran who stopped hemin prophylaxis at study entry: post hoc analyses from the phase 3 ENVISION study through month 362023/08/01English
HTRS2023.O6B.2 Allosteric regulation of coagulation factor IXa2023/08/01English
HTRS2023.P2.18 Pediatric persons with hemophilia A on EHL-FVIII or emicizumab prophylaxis require iron therapy despite low annualized bleeding rate2023/08/01English
Author Index2023/08/01English
HTRS2023.P3.1 Iron deficiency in a large pediatric comprehensive bleeding disorders clinic: current screening practice and iron deficiency prevalence2023/08/01English
HTRS2023.P1.5 Macrothrombocytopenia, significantly elevated IPF, and severe epistaxis mistaken for ITP: a case report of GNE-related thrombocytopenia2023/08/01English
HTRS2023.O6B.4 FXIII-mediated cross-linking of hepatic fibrin is a critical driver of platelet accumulation and liver regeneration after partial hepatectomy2023/08/01English
HTRS2023.P2.7 Burden of disease and impact on quality of life in hereditary factor X deficiency patients receiving prophylaxis: findings from the Hereditary Factor X Deficiency in America survey2023/08/01English
HTRS2023.P2.3 F8 variants in women and girls evaluated for hemophilia A2023/08/01English
HTRS2023.P2.9 Fitusiran prophylaxis demonstrates sustained bleed protection in people with hemophilia A or B: an exploratory analysis of antithrombin levels and peak thrombin generation from three phase 3 trials2023/08/01English
HTRS2023.P4.3 Identifying barriers and facilitators to inform implementation strategies for venous thromboembolism prevention in oncology practice using the Implementation Research Logic Model2023/08/01English
HTRS2023.P4.2 Improving judicious use of heparin induced thrombocytopenia laboratory testing using a clinician decision support tool2023/08/01English
HTRS2023.P2.5 Joint surveillance with ultrasound in pediatric hemophilia A patients on emicizumab: a single institution retrospective review2023/08/01English
HTRS2023.P2.11 Personalized prophylaxis with simoctocog alfa in adult Japanese previously treated patients with severe hemophilia A2023/08/01English
HTRS2023.P2.6 Burden of disease and impact on quality of life in hereditary factor X deficiency patients who have experienced menorrhagia: findings from the Hereditary Factor X Deficiency in America survey2023/08/01English
HTRS2023.O8C.2 Eptacog beta efficacy and safety in underweight, normal weight, and overweight/obese persons with hemophilia A or B and inhibitors2023/08/01English
HTRS2023.O6A.1 Leveraging quantitative platelet adhesion and platelet geometry-sensing assays to evaluate platelet function in type 1 von Willebrand disease2023/08/01English
Long-term outcomes of prophylaxis with a recombinant factor VIII Fc or recombinant factor IX Fc in patients with hemophilia previously treated on demand2023/08/01English
Thromboembolism in nephrotic syndrome: controversies and uncertainties2023/08/01English